The Swedish specialty pharmaceutical company Pharmalink AB has raised SEK 100 million (€10.5 million) to prepare for a Phase 3 development programme of its candidate product for primary IgA nephropathy, an inflammatory disease of the kidney. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
